Brief: Cue Biopharma Reports Confirmed Partial Response (Pr) In Ongoing Phase 1 Monotherapy Study Of Cue-101 In Late Stage Second Line And Beyond Patients With Hpv+ Recurrent/Metastatic Head And Neck Cancer
10/05/2021 13:42
May 10 (Reuters) - Cue Biopharma Inc CUE.O :
* CUE BIOPHARMA REPORTS CONFIRMED PARTIAL RESPONSE (PR) IN
ONGOING
PHASE 1 MONOTHERAPY STUDY OF CUE-101 IN LATE STAGE SECOND LINE
AND BEYOND PATIENTS WITH HPV+ RECURRENT/METASTATIC HEAD AND NECK
CANCER
* CUE BIOPHARMA - PARTIAL RESPONSE DATA SHOWS ACTIVITY OF
CUE-101
AS MONOTHERAPY IN PATIENT
Source text for Eikon: ID:nGNX8Z3NMt
Further company coverage: CUE.O
((reuters.briefs@thomsonreuters.com;))